FDA briefing docs signal likely approval of Moderna's mRNA flu shot
- FDA posted briefing materials ahead of June 18 VRBPAC meeting on mFlusiva (mRNA-1010) flu vaccine
- Documents noted immune response data may support effectiveness in adults 65+ and superior efficacy vs standard shots in 50-64 group
- Viewed as surprisingly positive given prior regulatory scrutiny of mRNA flu application
- Moderna also announced same-day organizational changes expanding leadership for 2027-2028 launches including flu and oncology products
- Stock surged ~10% to ~$57 intraday from $52.13 prior close on heavy volume
- Moves tied directly to pipeline momentum in vaccines per IBD and press releases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.